Comparison of Different Vascular Biomarkers for Predicting In-Hospital Mortality in Severe SARS-CoV-2 Infection

Renáta Sütő,Marianna Pócsi,Miklós Fagyas,Edit Kalina,Zsolt Fejes,Zoltán Szentkereszty,János Kappelmayer,Béla Nagy,Béla Nagy Jr.

DOI: https://doi.org/10.3390/microorganisms12010229

IF: 4.5

2024-01-22

Microorganisms

Abstract:Severe SARS-CoV-2 elicits a hyper-inflammatory response that results in intravascular inflammation with endothelial injury, which contributes to increased mortality in COVID-19. To predict the outcome of severe SARS-CoV-2 infection, we analyzed the baseline level of different biomarkers of vascular disorders in COVID-19 subjects upon intensive care unit (ICU) admission and prior to any vaccination. A total of 70 severe COVID-19 patients (37 survivors and 33 non-survivors) were included with 16 age- and sex-matched controls. Vascular dysfunction was monitored via soluble VCAM-1, E-selectin, ACE2 and Lp-PLA2, while abnormal platelet activation was evaluated by soluble P-selectin and CD40L in parallel. These results were correlated with routine laboratory parameters and disease outcomes. Among these parameters, VCAM-1 and ACE2 showed significantly higher serum levels in COVID-19 patients with early death vs. convalescent subjects. VCAM-1 was significantly correlated with the Horowitz index (r = 0.3115) and IL-6 (r = 0.4599), while ACE2 was related to E-selectin (r = 0.4143) and CD40L (r = 0.2948). Lp-PLA2 was altered in none of these COVID-19 subcohorts and showed no relationship with the other parameters. Finally, the pre-treatment level of VCAM-1 (≥1420 ng/mL) and ACE2 activity (≥45.2 μU/mL) predicted a larger risk for mortality (Log-Rank p = 0.0031 and p = 0.0117, respectively). Vascular dysfunction with endothelial cell activation is linked to lethal COVID-19, and highly elevated soluble VCAM-1 and ACE2 at admission to ICU may predict unfavorable outcomes.

microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to predict in - hospital mortality in severe SARS - CoV - 2 infection by comparing different vascular biomarkers. Specifically, the researchers analyzed the baseline levels of different biomarkers of vascular disorders in severe COVID - 19 patients at the time of admission to the intensive care unit (ICU), and evaluated the relationship between these biomarkers and the prognosis of the disease. The main purpose of the study was to determine which biomarkers can effectively predict the adverse outcomes of patients, especially the early risk of death.

### Research Background
- **Importance of the problem**: Severe SARS - CoV - 2 infection can lead to a high - inflammatory response, causing intravascular inflammation and endothelial cell damage, thereby increasing the mortality rate of COVID - 19 patients. Therefore, finding biomarkers that can effectively predict adverse outcomes is of great significance for improving the treatment and management of patients.
- **Research methods**: The researchers selected 70 severe COVID - 19 patients (37 survivors and 33 non - survivors), as well as 16 age - and - sex - matched control groups. By detecting the levels of biomarkers such as vascular cell adhesion molecule - 1 (VCAM - 1), E - selectin, angiotensin - converting enzyme 2 (ACE2), and lipoprotein - associated phospholipase A2 (Lp - PLA2) in serum, and correlating them with routine laboratory parameters and disease prognosis.

### Main Findings
- **Significant differences in VCAM - 1 and ACE2**: The study found that the serum levels of VCAM - 1 and ACE2 in non - survivors were significantly higher than those in survivors and the control group. VCAM - 1 was significantly correlated with the Horowitz index (r = 0.3115) and IL - 6 (r = 0.4599), while ACE2 was correlated with E - selectin (r = 0.4143) and CD40L (r = 0.2948).
- **No significant change in Lp - PLA2**: Lp - PLA2 did not change significantly in each subgroup and had no correlation with other parameters.
- **Predictive value**: Baseline VCAM - 1 levels (≥1420 ng/mL) and ACE2 activity (≥45.2 µU/mL) can effectively predict a higher risk of death (Log - Rank p = 0.0031 and p = 0.0117).

### Conclusions
- **Main conclusion**: Vascular dysfunction and endothelial cell activation are associated with fatal COVID - 19, and highly elevated soluble VCAM - 1 and ACE2 levels at ICU admission can predict adverse outcomes.
- **Clinical significance**: The detection of these biomarkers can provide important information for doctors, helping them to identify high - risk patients earlier and thus take more aggressive treatment measures.

### Formulas and Data
- **Correlation coefficients**:
- VCAM - 1 and Horowitz index: r = 0.3115
- VCAM - 1 and IL - 6: r = 0.4599
- ACE2 and E - selectin: r = 0.4143
- ACE2 and CD40L: r = 0.2948

- **Predictive values**:
- VCAM - 1: AUC = 0.6855 (95% CI [0.5595–0.8115], p = 0.0077)
- E - selectin: AUC = 0.6523 (95% CI [0.5215–0.7813], p = 0.0286)
- ACE2: AUC = 0.6519 (95% CI [0.5213–0.7826], p = 0.0291)

These results indicate that VCAM - 1 and ACE2 have important clinical application value in predicting the adverse outcomes of severe COVID - 19 patients.